AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 10325444 — intervention group
Group type: EXPERIMENTAL
Intervention: Silymarin (420 mg/day) + Tacrine (40 mg/day for 6 weeks, then increased to 80 mg/day for 6 weeks)
Number of subjects: 222
Study 10325444 — intervention group
Group type: COMPARATOR
Intervention: Tacrine + Placebo
Number of subjects: 222
Study 7544524 — intervention group
Group type: EXPERIMENTAL
Intervention: Consolidation therapy
Number of subjects: 1
Study 2027114 — intervention group
Group type: EXPERIMENTAL
Intervention: Orgotein (4 or 8 mg)
Number of subjects: 419
Study 2027114 — intervention group
Group type: COMPARATOR
Intervention: Betamethasone
Number of subjects: 419
Study 6909683 — intervention group
Group type: EXPERIMENTAL
Intervention: Indomethacin
Number of subjects: 21
Study 6909683 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 21
Study 31447483 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-pass genome sequencing (GS)
Number of subjects: 1023
Study 29363535 — intervention group
Group type: EXPERIMENTAL
Intervention: Endocuff Vision (EAC)
Number of subjects: 1772
Study 29363535 — intervention group
Group type: COMPARATOR
Intervention: Standard Colonoscopy (SC)
Number of subjects: 1772
Study 27825551 — intervention group
Group type: EXPERIMENTAL
Intervention: 30s recovery
Number of subjects: 10
Study 27825551 — intervention group
Group type: COMPARATOR
Intervention: 180s recovery
Number of subjects: 10
Study 27825551 — intervention group
Group type: EXPERIMENTAL
Intervention: Both recovery times
Number of subjects: 10
Study 25892348 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.2% ropivacaine
Number of subjects: 82
Study 25892348 — intervention group
Group type: COMPARATOR
Intervention: 0.9% normal saline (placebo)
Number of subjects: 82
Study 23650901 — intervention group
Group type: EXPERIMENTAL
Intervention: Patch pump (PP)
Number of subjects: 20
Study 23650901 — intervention group
Group type: COMPARATOR
Intervention: Conventional pump (CP)
Number of subjects: 20
Study 21896198 — intervention group
Group type: EXPERIMENTAL
Intervention: 7% hypertonic saline (HS)
Number of subjects: 12
Study 21896198 — intervention group
Group type: COMPARATOR
Intervention: 0.12% saline (placebo)
Number of subjects: 12
Study 19781874 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotics
Number of subjects: 0
Study 19781874 — intervention group
Group type: EXPERIMENTAL
Intervention: Prebiotics
Number of subjects: 0
Study 19781874 — intervention group
Group type: EXPERIMENTAL
Intervention: Related agents
Number of subjects: 0
Study 19781874 — intervention group
Group type: EXPERIMENTAL
Intervention: Cautious approach based on scientific data
Number of subjects: 0
Study 18159013 — intervention group
Group type: EXPERIMENTAL
Intervention: Early goal-directed therapy (EGDT)
Number of subjects: 273
Study 18159013 — intervention group
Group type: COMPARATOR
Intervention: Conventional empirical therapy (Control)
Number of subjects: 273
Study 15321022 — intervention group
Group type: EXPERIMENTAL
Intervention: Grid laser photocoagulation and 0.5 mL of 40 mg/mL posterior subtenon triamcinolone
Number of subjects: 31
Study 15321022 — intervention group
Group type: COMPARATOR
Intervention: Grid laser photocoagulation only
Number of subjects: 31
Study 12646340 — intervention group
Group type: EXPERIMENTAL
Intervention: rosuvastatin 10 mg
Number of subjects: 615
Study 12646340 — intervention group
Group type: COMPARATOR
Intervention: atorvastatin 10 mg
Number of subjects: 615
Study 12646340 — intervention group
Group type: COMPARATOR
Intervention: simvastatin 20 mg
Number of subjects: 615
Study 12646340 — intervention group
Group type: COMPARATOR
Intervention: pravastatin 20 mg
Number of subjects: 615
Study 10068342 — intervention group
Group type: EXPERIMENTAL
Intervention: Tissue PSA (T-PSA)
Number of subjects: 104
Study 10068342 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum PSA (S-PSA)
Number of subjects: 104
Study 7556733 — intervention group
Group type: EXPERIMENTAL
Intervention: Novel conjunctival incision technique
Number of subjects: 13
Study 7556733 — intervention group
Group type: COMPARATOR
Intervention: Conventional surgery
Number of subjects: 13
Study 2330116 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of levodopa and carbidopa
Number of subjects: 6
Study 2330116 — intervention group
Group type: COMPARATOR
Intervention: Levodopa alone
Number of subjects: 6
Study 7408140 — intervention group
Group type: EXPERIMENTAL
Intervention: Dipyridamole (Persantine) and aspirin
Number of subjects: 2026
Study 7408140 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 2026
Study 31912785 — intervention group
Group type: EXPERIMENTAL
Intervention: Electronic symptom monitoring intervention
Number of subjects: 766
Study 31912785 — intervention group
Group type: COMPARATOR
Intervention: Usual oncology care
Number of subjects: 766
Study 30232855 — intervention group
Group type: EXPERIMENTAL
Intervention: Warming needle moxibustion
Number of subjects: 60
Study 30232855 — intervention group
Group type: COMPARATOR
Intervention: Conventional acupuncture
Number of subjects: 60
Study 26849264 — intervention group
Group type: EXPERIMENTAL
Intervention: Solvent exposure
Number of subjects: 481
Study 26849264 — intervention group
Group type: COMPARATOR
Intervention: Endotoxin and metals exposure
Number of subjects: 481
Study 24275067 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients' contribution to the alliance
Number of subjects: 133
Study 24275067 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapists' contribution to the alliance
Number of subjects: 133
Study 24275067 — intervention group
Group type: COMPARATOR
Intervention: Therapist effects
Number of subjects: 133
Study 22434051 — intervention group
Group type: EXPERIMENTAL
Intervention: High GI high carbohydrate meal (HGI-HC)
Number of subjects: 32
Study 22434051 — intervention group
Group type: EXPERIMENTAL
Intervention: Low GI high carbohydrate meal (LGI-HC)
Number of subjects: 32
Study 22434051 — intervention group
Group type: EXPERIMENTAL
Intervention: Low GI moderately high in protein and fat meal (LGI-MPF)
Number of subjects: 32
Study 22434051 — intervention group
Group type: COMPARATOR
Intervention: All meals (HGI-HC, LGI-HC, LGI-MPF)
Number of subjects: 32
Study 20339615 — intervention group
Group type: EXPERIMENTAL
Intervention: DTPw-HepB-Hib fully liquid vaccine
Number of subjects: 0
Study 20339615 — intervention group
Group type: COMPARATOR
Intervention: DTPw and Hib vaccines administered separately
Number of subjects: 0
Study 18311434 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxybutynin
Number of subjects: 8
Study 18311434 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 15811188 — intervention group
Group type: EXPERIMENTAL
Intervention: Latanoprost
Number of subjects: 42
Study 15811188 — intervention group
Group type: EXPERIMENTAL
Intervention: Bimatoprost
Number of subjects: 42
Study 15811188 — intervention group
Group type: EXPERIMENTAL
Intervention: Dorzolamide
Number of subjects: 42
Study 12459614 — intervention group
Group type: EXPERIMENTAL
Intervention: Cassava flour ('seca')
Number of subjects: 19
Study 12459614 — intervention group
Group type: EXPERIMENTAL
Intervention: Cassava flour ('d'água')
Number of subjects: 19
Study 12459614 — intervention group
Group type: COMPARATOR
Intervention: Sweet made from cupuaçú (positive control)
Number of subjects: 19
Study 12459614 — intervention group
Group type: COMPARATOR
Intervention: Fish (tambaqui) (negative control)
Number of subjects: 19
Study 11039639 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-intensity exercise group
Number of subjects: 0
Study 11039639 — intervention group
Group type: EXPERIMENTAL
Intervention: High-intensity exercise group
Number of subjects: 0
Study 11039639 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise (general)
Number of subjects: 0
Study 8970607 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluvastatin 20 mg/day
Number of subjects: 20
Study 1894496 — intervention group
Group type: EXPERIMENTAL
Intervention: Active PEMF therapy (pulsed electromagnetic fields)
Number of subjects: 19
Study 1894496 — intervention group
Group type: COMPARATOR
Intervention: Inactive PEMF therapy (control)
Number of subjects: 19
Study 6361794 — intervention group
Group type: EXPERIMENTAL
Intervention: Suprofen 200 mg
Number of subjects: 130
Study 6361794 — intervention group
Group type: EXPERIMENTAL
Intervention: Suprofen 400 mg
Number of subjects: 130
Study 6361794 — intervention group
Group type: EXPERIMENTAL
Intervention: Diflunisal 750 mg
Number of subjects: 130
Study 6361794 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 130
Study 30569790 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine (3 mg·kg‐1 of body mass)
Number of subjects: 21
Study 30569790 — intervention group
Group type: COMPARATOR
Intervention: Placebo (3 mg·kg‐1 of body mass of dextrose)
Number of subjects: 21
Study 30176391 — intervention group
Group type: EXPERIMENTAL
Intervention: Resveratrol supplementation for 16 weeks
Number of subjects: 66
Study 30176391 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 66
Study 26275787 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance exercise (leg press, chest press, knee flexion, lat pulldown, knee extension at 65% one-repetition maximum for three sets of 10 repetitions)
Number of subjects: 36
Study 26275787 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance exercise
Number of subjects: 36
Study 26275787 — intervention group
Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 36
Study 25147092 — intervention group
Group type: EXPERIMENTAL
Intervention: Chewing gum
Number of subjects: 109
Study 25147092 — intervention group
Group type: COMPARATOR
Intervention: Routine care
Number of subjects: 109
Study 22465901 — intervention group
Group type: EXPERIMENTAL
Intervention: Wellmune (250 mg once daily)
Number of subjects: 100
Study 22465901 — intervention group
Group type: COMPARATOR
Intervention: Placebo (identical rice flour-based)
Number of subjects: 100
Study 20044683 — intervention group
Group type: COMPARATOR
Intervention: Methylprednisolone (40 mg)
Number of subjects: 58
Study 20044683 — intervention group
Group type: EXPERIMENTAL
Intervention: Tenoxicam (20 mg)
Number of subjects: 58
Study 17963483 — intervention group
Group type: EXPERIMENTAL
Intervention: Interactive computer-based intervention
Number of subjects: 0
Study 17963483 — intervention group
Group type: COMPARATOR
Intervention: Standard information website (control)
Number of subjects: 0
Study 15905884 — intervention group
Group type: EXPERIMENTAL
Intervention: Guolin qigong
Number of subjects: 88
Study 15905884 — intervention group
Group type: COMPARATOR
Intervention: Conventional exercise
Number of subjects: 88
Study 15905884 — intervention group
Group type: COMPARATOR
Intervention: Guolin qigong and Conventional exercise
Number of subjects: 88
Study 11835040 — intervention group
Group type: EXPERIMENTAL
Intervention: Abciximab
Number of subjects: 89
Study 11835040 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 89
Study 11835040 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiogenic shock
Number of subjects: 89
Study 9895080 — intervention group
Group type: EXPERIMENTAL
Intervention: remifentanil 0.04 microg x kg(‐1) x min(‐1)
Number of subjects: 160
Study 9895080 — intervention group
Group type: EXPERIMENTAL
Intervention: remifentanil 0.07 microg x kg(‐1) x min(‐1)
Number of subjects: 160
Study 9895080 — intervention group
Group type: EXPERIMENTAL
Intervention: remifentanil 0.1 microg x kg(‐1) x min(‐1)
Number of subjects: 160
Study 9895080 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 160
Study 9895080 — intervention group
Group type: EXPERIMENTAL
Intervention: remifentanil (all doses)
Number of subjects: 160
Study 7735336 — intervention group
Group type: EXPERIMENTAL
Intervention: GHRH + Arginine (0.5 g/kg infused over 30 min)
Number of subjects: 30
Study 7735336 — intervention group
Group type: EXPERIMENTAL
Intervention: GHRH + Pyridostigmine (120 mg orally at -60 min)
Number of subjects: 30
Study 7735336 — intervention group
Group type: COMPARATOR
Intervention: GHRH alone (1 microgram/kg i.v. at 0 min)
Number of subjects: 30
Study 8182272 — intervention group
Group type: EXPERIMENTAL
Intervention: 25 units of viral protein antigen
Number of subjects: 0
Study 8182272 — intervention group
Group type: COMPARATOR
Intervention: 12.5 units of viral protein antigen
Number of subjects: 0
Study 8182272 — intervention group
Group type: COMPARATOR
Intervention: 6.25 units of viral protein antigen
Number of subjects: 0
Study 8182272 — intervention group
Group type: COMPARATOR
Intervention: All doses
Number of subjects: 0
Study 3002577 — intervention group
Group type: EXPERIMENTAL
Intervention: Lumpectomy (L)
Number of subjects: 78
Study 3002577 — intervention group
Group type: EXPERIMENTAL
Intervention: Lumpectomy with postoperative irradiation (LX)
Number of subjects: 78
Study 3002577 — intervention group
Group type: COMPARATOR
Intervention: Lumpectomy without postoperative irradiation (LO)
Number of subjects: 78
Study 3002577 — intervention group
Group type: EXPERIMENTAL
Intervention: Total mastectomy (TM)
Number of subjects: 78
Study 31597496 — intervention group
Group type: EXPERIMENTAL
Intervention: S-1
Number of subjects: 0
Study 31597496 — intervention group
Group type: COMPARATOR
Intervention: gemcitabine
Number of subjects: 0
Study 29150790 — intervention group
Group type: EXPERIMENTAL
Intervention: Yishen Qufeng Shengshi Recipe (YQSR), 200 mL, twice per day, orally for 6 months
Number of subjects: 145
Study 29150790 — intervention group
Group type: COMPARATOR
Intervention: Losartan, 50 mg/d orally for 6 months
Number of subjects: 145
Study 29150790 — intervention group
Group type: EXPERIMENTAL
Intervention: Yishen Qufeng Shengshi Recipe (YQSR)
Number of subjects: 145
Study 26806592 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional canola oil
Number of subjects: 0
Study 26806592 — intervention group
Group type: EXPERIMENTAL
Intervention: High oleic canola oil
Number of subjects: 0
Study 26806592 — intervention group
Group type: EXPERIMENTAL
Intervention: High oleic canola oil enriched with DHA
Number of subjects: 0
Study 26806592 — intervention group
Group type: EXPERIMENTAL
Intervention: Flax/safflower oil blend
Number of subjects: 0
Study 26806592 — intervention group
Group type: EXPERIMENTAL
Intervention: Corn/safflower oil blend
Number of subjects: 0
Study 26806592 — intervention group
Group type: EXPERIMENTAL
Intervention: SNP rs324420 carriers
Number of subjects: 0
Study 26506579 — intervention group
Group type: EXPERIMENTAL
Intervention: Family-Based Treatment for Adolescent Bulimia Nervosa (FBT-BN)
Number of subjects: 130
Study 26506579 — intervention group
Group type: COMPARATOR
Intervention: Cognitive-Behavioral Therapy adapted for adolescents (CBT-A)
Number of subjects: 130
Study 23372142 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium channel blockade (CCB) - 60 mg oral nimodipine
Number of subjects: 23
Study 23372142 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23
Study 21912808 — intervention group
Group type: EXPERIMENTAL
Intervention: Erythropoietin (EPO) treatment
Number of subjects: 163
Study 21912808 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 163
Study 19233107 — intervention group
Group type: EXPERIMENTAL
Intervention: Network-led care for severe heart failure
Number of subjects: 0
Study 19233107 — intervention group
Group type: COMPARATOR
Intervention: Conventional management for severe heart failure (control group)
Number of subjects: 0
Study 16646722 — intervention group
Group type: EXPERIMENTAL
Intervention: Verum acupuncture based on Traditional Chinese Medicine (TCM)
Number of subjects: 0
Study 16646722 — intervention group
Group type: COMPARATOR
Intervention: Sham acupuncture
Number of subjects: 0
Study 14656278 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination chemotherapy
Number of subjects: 0
Study 14656278 — intervention group
Group type: COMPARATOR
Intervention: Single-agent chemotherapy (carboplatin or new drug)
Number of subjects: 0
Study 14656278 — intervention group
Group type: EXPERIMENTAL
Intervention: Platinum combination-based therapy
Number of subjects: 0
Study 14656278 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-agent carboplatin
Number of subjects: 0
Study 14656278 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-agent new drug
Number of subjects: 0
Study 11025952 — intervention group
Group type: EXPERIMENTAL
Intervention: Amrinone infusion (17 patients)
Number of subjects: 46
Study 11025952 — intervention group
Group type: EXPERIMENTAL
Intervention: Milrinone infusion (15 patients)
Number of subjects: 46
Study 11025952 — intervention group
Group type: EXPERIMENTAL
Intervention: Olprinone infusion (14 patients)
Number of subjects: 46
Study 9710028 — intervention group
Group type: EXPERIMENTAL
Intervention: Selegiline
Number of subjects: 157
Study 9710028 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 157
Study 8311271 — intervention group
Group type: EXPERIMENTAL
Intervention: Lumbar epidural sufentanil
Number of subjects: 22
Study 8311271 — intervention group
Group type: COMPARATOR
Intervention: Thoracic epidural sufentanil
Number of subjects: 22
Study 3396573 — intervention group
Group type: EXPERIMENTAL
Intervention: 12% glucose/electrolyte beverage (HC)
Number of subjects: 15
Study 3396573 — intervention group
Group type: EXPERIMENTAL
Intervention: 6% glucose/electrolyte beverage (MC)
Number of subjects: 15
Study 3396573 — intervention group
Group type: EXPERIMENTAL
Intervention: flavored water placebo (P)
Number of subjects: 15
Study 30525053 — intervention group
Group type: EXPERIMENTAL
Intervention: Corneal Subbasal Nerve Plexus (SNP) changes in severe DNOAP patients using in vivo Corneal Confocal Microscopy (CCM)
Number of subjects: 26
Study 30525053 — intervention group
Group type: COMPARATOR
Intervention: Healthy control group
Number of subjects: 26
Study 26603531 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma prekallikrein (PK) levels in the highest 10th percentile
Number of subjects: 636
Study 26603531 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma prekallikrein (PK) levels
Number of subjects: 636
Study 23266575 — intervention group
Group type: EXPERIMENTAL
Intervention: 2-COM communication tool
Number of subjects: 0
Study 23266575 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual
Number of subjects: 0
Study 22928779 — intervention group
Group type: EXPERIMENTAL
Intervention: 2v2 small-sided games
Number of subjects: 16
Study 22928779 — intervention group
Group type: COMPARATOR
Intervention: 4v4 small-sided games
Number of subjects: 16
Study 22928779 — intervention group
Group type: EXPERIMENTAL
Intervention: Full court games
Number of subjects: 16
Study 22928779 — intervention group
Group type: COMPARATOR
Intervention: Half court games
Number of subjects: 16
Study 20116961 — intervention group
Group type: EXPERIMENTAL
Intervention: Engaging Moms Program (EMP)
Number of subjects: 62
Study 20116961 — intervention group
Group type: COMPARATOR
Intervention: Intensive Case Management Services (ICMS)
Number of subjects: 62
Study 18329261 — intervention group
Group type: EXPERIMENTAL
Intervention: Fatty fish or long-chain n-3 PUFA intake higher than 0.10% of energy intake
Number of subjects: 0
Study 18329261 — intervention group
Group type: EXPERIMENTAL
Intervention: Fatty fish intake
Number of subjects: 0
Study 16306858 — intervention group
Group type: EXPERIMENTAL
Intervention: THC (10 mg)
Number of subjects: 24
Study 16306858 — intervention group
Group type: EXPERIMENTAL
Intervention: Cannabis extract (10 mg THC + 5.4 mg CBD)
Number of subjects: 24
Study 16306858 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 16221650 — intervention group
Group type: EXPERIMENTAL
Intervention: Group therapy
Number of subjects: 13
Study 16221650 — intervention group
Group type: COMPARATOR
Intervention: Control group (no group therapy)
Number of subjects: 13
Study 9140674 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicardipine SR (40‐80 mg for 21 months)
Number of subjects: 20
Study 9140674 — intervention group
Group type: EXPERIMENTAL
Intervention: Alacepril (25‐100 mg for 18 months)
Number of subjects: 20
Study 2626193 — intervention group
Group type: EXPERIMENTAL
Intervention: S-adenosyl-L-methionine
Number of subjects: 200
Study 2626193 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 200
Study 180198 — intervention group
Group type: EXPERIMENTAL
Intervention: Adenine arabinoside for five days
Number of subjects: 87
Study 180198 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 87
Study 30685685 — intervention group
Group type: EXPERIMENTAL
Intervention: Three-drug combination chemotherapy with methotrexate, doxorubicin, and cisplatin (standard chemotherapy)
Number of subjects: 2260
Study 29229055 — intervention group
Group type: EXPERIMENTAL
Intervention: Upper cervical translatoric spinal mobilization (UC‐TSM)
Number of subjects: 82
Study 29229055 — intervention group
Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 82
Study 25851756 — intervention group
Group type: EXPERIMENTAL
Intervention: Weekly azathioprine 300 mg pulse
Number of subjects: 60
Study 25851756 — intervention group
Group type: COMPARATOR
Intervention: Daily azathioprine 100 mg
Number of subjects: 60
Study 24040156 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational intervention (one-off group session with DVD, educational booklet, self-monitoring diary, and worksheet)
Number of subjects: 97
Study 24040156 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational intervention
Number of subjects: 97
Study 24040156 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 97
Study 21860192 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevoflurane
Number of subjects: 180
Study 21860192 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoflurane
Number of subjects: 180
Study 21860192 — intervention group
Group type: COMPARATOR
Intervention: Total Intravenous Anesthesia (TIVA)
Number of subjects: 180
Study 19318695 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous tezosentan at 0.2 mg/h for 24 hours followed by 1.0 mg/h for 24 hours (cohort I)
Number of subjects: 21
Study 19318695 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous tezosentan at 1.0 mg/h for 24 hours followed by 5.0 mg/h for 24 hours (cohort II)
Number of subjects: 21
Study 19318695 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous tezosentan (cohort III)
Number of subjects: 21
Study 19318695 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study 17349087 — intervention group
Group type: EXPERIMENTAL
Intervention: Rolled oat (O)
Number of subjects: 8
Study 17349087 — intervention group
Group type: COMPARATOR
Intervention: Defatted rolled oat (DO)
Number of subjects: 8
Study 17349087 — intervention group
Group type: COMPARATOR
Intervention: Rolled whole wheat (W)
Number of subjects: 8
Study 17349087 — intervention group
Group type: COMPARATOR
Intervention: Rolled whole wheat with added oat fat (WF)
Number of subjects: 8